EVISA Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).

Supporters of EVISA includes:


an international, scientific, peer-reviewed, open access journal on biomedicines published monthly online by MDPI.



Source type
First volume
Last volume
Publish city

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, nanosimilars, and nano-biosimilars. The journal is open for the publication of studies conducted at the basic science, clinical development, and clinical trial stages. Furthermore, publications that address safety, pharmacovigilance regulatory, and ethical issues are welcome. We invite you to consider submitting your work to Biomedicines, be it original research or review articles, or toward developing Special Issues of current key topics. 

The aim of Biomedicines is to publish high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development and, ultimately, to clinical use. Therefore, basic research, comprehensive preclinical studies, clinical development, and clinical trials are all within the scope of the journal.


  • Pathogenesis and mechanisms of diseases
  • Translational medical research
  • Biomaterial in biomedical research
  • Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology
  • Biomarker discovery and early diagnosis research
  • Drug discovery and drug development, biomedicine, and pharmacotherapy
  • Natural biomedicine, including marine, plant, and animal-derived biomedicine
  • Biopharmaceutical biomedicine: biologics and biosimilars
  • Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bio-imaging, gene therapy, vaccine, cell therapy, and tissue engineering
  • Pharmacovigilance, regulatory, and ethical issues

Imprint     Disclaimer

© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )